Shares of Hikma Pharmaceuticals PLC HIK inched up 0.52% to £19.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...

According to researchers, participants taking spironolactone (with or without colchicine) had a 31% lower risk of new or worsening HF than people taking colchicine with placebo or two placebos (1.6% ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

In H. Lundbeck A-S v. Lupin Ltd., Case No. 2022-1194 (Fed. Circ. December 7, 2023), Plaintiffs, H. Lundbeck A/S (“Lundbeck”) and Takeda Pharmaceutical Company Ltd ...

Using the 2 Stage Free Cash Flow to Equity, Hikma Pharmaceuticals fair value estimate is UK£37.96 Analyst price target for HIK is US$23.28 which is 39% below our fair value estimate In this ...

Japanese pharmaceutical giant Takeda on Thursday raised the bar for sustainability in the biotech manufacturing sector, with one of its buildings now being able to produce more renewable energy ...

4) CLEAR SYNERGY, dual trials on the use of spironolactone vs. placebo and colchicine vs. placebo in patients with myocardial infarction, and 5) Project My Heart Your Heart, developing a protocol of ...

在全球制药行业中，Hikma药业无疑是一个闪亮的名字。自1978年在约旦创立以来，Hikma在仿制药领域崭露头角，2021年的总销售额高达25.53亿美元，成为行业中的佼佼者。那么，Hikma究竟凭借什么成功逆袭到今天的辉煌地位？本文将揭示Hikma仿制药企业的成功秘籍 ...

Takeda’s stem cell platforms aim to improve treatment options for both solid tumours and blood cancers. Credit: PeopleImages.com – Yuri A via Shutterstock. Takeda and Alloy Therapeutics have announced ...

Colchicine, an ancient drug with a well-established safety record, that is now approved for secondary prevention of atherosclerosis based upon its proven efficacy and safety. In a recent meta-analysis ...

This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are filed pursuant to the Hatch-Waxman Act. It also includes the same ...

The analysis included 120 participants with painful knee OA and radiographic Kellgren-Lawrence (KL) grades 2 or 3 who were randomly assigned to daily colchicine or placebo (1:1) for 12 weeks.